Search

Your search keyword '"Hartmann, Karin"' showing total 951 results

Search Constraints

Start Over You searched for: Author "Hartmann, Karin" Remove constraint Author: "Hartmann, Karin"
951 results on '"Hartmann, Karin"'

Search Results

2. Post-transplant Inflammatory Bowel Disease Associated with Donor-Derived TIM-3 Deficiency

5. Serum chemistry profiling and prognostication in systemic mastocytosis: a registry-based study of the ECNM and GREM

9. Tumor necrosis factor α promotes clonal dominance of KIT D816V+ cells in mastocytosis: role of survivin and impact on prognosis

11. The Normal Range of Baseline Tryptase Should Be 1 to 15 ng/mL and Covers Healthy Individuals With HαT

13. Food-Induced Anaphylaxis: Data From the European Anaphylaxis Registry

14. European Competence Network on Mastocytosis (ECNM): 20-Year Jubilee, Updates, and Future Perspectives

15. Mast cell leukemia: clinical and molecular features and survival outcomes of patients in the ECNM Registry

16. Prognostic Impact of Organomegaly in Mastocytosis: An Analysis of the European Competence Network on Mastocytosis

19. Prevalence of hypersensitivity reactions in various forms of mastocytosis: A pilot study of 2485 adult patients with mastocytosis collected in the ECNM registry

21. Mast Cell Diseases in Practice and Research: Issues and Perspectives Raised by Patients and Their Recommendations to the Scientific Community and Beyond

22. Refined Treatment Response Criteria for Indolent Systemic Mastocytosis Proposed by the ECNM-AIM Consortium

23. Standards of Pathology in the Diagnosis of Systemic Mastocytosis: Recommendations of the EU-US Cooperative Group

24. Proposed European Competence Network on Mastocytosis—American Initiative in Mast Cell Diseases (ECNM-AIM) Response Criteria in Advanced Systemic Mastocytosis

25. Global Classification of Mast Cell Activation Disorders: An ICD-10-CM–Adjusted Proposal of the ECNM-AIM Consortium

26. Personalized Management Strategies in Mast Cell Disorders: ECNM-AIM User’s Guide for Daily Clinical Practice

27. Standards of Genetic Testing in the Diagnosis and Prognostication of Systemic Mastocytosis in 2022: Recommendations of the EU-US Cooperative Group

28. Refined diagnostic criteria for bone marrow mastocytosis: a proposal of the European competence network on mastocytosis

30. Ambient pollen exposure and pollen allergy symptom severity in the EPOCHAL study.

33. Prevalence Of The KIT D816V Mutation In Peripheral Blood (PB) Of Patients With Evidence Of Systemic Mast Cell Activation (MCA): Results Of The Prospective, Multi-centered, Global PROSPECTOR Clinical Trial

34. Reductions in Polypharmacy for Patients with Indolent Systemic Mastocytosis on Avapritinib

35. Avapritinib Decreased Symptom Burden in Patients With Indolent Systemic Mastocytosis in the Registrational Double-Blind, Placebo-Controlled PIONEER Study

36. Exploring the Spectrum of Indolent Systemic Mastocytosis: Analysis of High-Risk Disease Features in the PIONEER Study

37. Selecting the Right Criteria and Proper Classification to Diagnose Mast Cell Activation Syndromes: A Critical Review

40. Clinical Impact of Skin Lesions in Mastocytosis: A Multicenter Study of the European Competence Network on Mastocytosis

41. COVID-19 Vaccination in Mastocytosis: Recommendations of the European Competence Network on Mastocytosis (ECNM) and American Initiative in Mast Cell Diseases (AIM)

43. Scoring the Risk of Having Systemic Mastocytosis in Adult Patients with Mastocytosis in the Skin

44. Practical handling of allergic reactions to COVID-19 vaccines: A position paper from German and Austrian Allergy Societies AeDA, DGAKI, GPA and ÖGAI

45. Severe allergic reactions after COVID-19 vaccination with the Pfizer/BioNTech vaccine in Great Britain and USA: Position statement of the German Allergy Societies: Medical Association of German Allergologists (AeDA), German Society for Allergology and Clinical Immunology (DGAKI) and Society for Pediatric Allergology and Environmental Medicine (GPA)

46. Risk and management of patients with mastocytosis and MCAS in the SARS-CoV-2 (COVID-19) pandemic: Expert opinions

48. TNF alpha promotes clonal dominance of KIT D816V+ cells in mastocytosis: role of survivin and impact on prognosis

Catalog

Books, media, physical & digital resources